IP Library › Granted Patent US 8,481,085
Granted Patent B2
US 8,481,085 · App. 11/760,364 · Granted Jul 9, 2013

Pharmaceutical compositions comprising cannabigerol

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,481,085
App. No.
11/760,364
Granted
Jul 9, 2013
Kind
B2
Abstract

The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.

Claims (1)

1. A method of treating a bipolar or unipolar mood disorder in a human in need thereof comprising administering to the human a therapeutically effective amount of isolated cannabigerol, wherein the isolated cannabigerol is administered as a unit dosage form that comprises the isolated cannabigerol in an amount of from 0.1 mg to 1000 mg, and wherein the isolated cannabigerol is not administered as an inhaled vapor.

Assignments (3)
CHANGE OF NAME Recorded May 13, 2025
From: GW PHARMA LIMITED
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED
Reel/Frame 071097/0088 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2007
From: MUSTY, RICHARD; DEYO, RICHARD
To: GW PHARMA LIMITED
Reel/Frame 019911/0293 →